Comparing two cholesterol treatment approaches for early heart disease

This study is testing whether a combination of low-dose rosuvastatin and ezetimibe works as well as a higher dose of rosuvastatin alone for treating people with early coronary artery disease. Both approaches lower cholesterol in similar ways, but researchers want to know if the combination approach might cause fewer side effects while being equally effective.

High-dose cholesterol medications can cause muscle problems, liver issues, and other side effects—especially in patients from East Asia. This trial explores whether combining two lower-dose medications might provide the same heart protection with fewer unwanted effects, and whether medication is truly helpful for patients with only mild to moderate blockages in their arteries.